SCHEMBL4828877

SCHEMBL4828877

Cc1cccc(NC(=O)N(c2ccccc2)c2ccnc(NC(C)C(C)(C)O)n2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.68
AURKA O14965 2/20 0.40
AURKB Q96GD4 2/20 0.40
CDC7 O00311 1/20 0.40
PLK4 O00444 1/20 0.40
CHEK1 O14757 1/20 0.40
PDPK1 O15530 1/20 0.40
DAPK3 O43293 1/20 0.40
DYRK3 O43781 1/20 0.40
ROCK2 O75116 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
CHEK2 O96017 1/20 0.40
CDK1 P06493 1/20 0.40
CSF1R P07333 1/20 0.40
RET P07949 1/20 0.40
MET P08581 1/20 0.40
PIM1 P11309 1/20 0.40
FGFR1 P11362 1/20 0.40
SRC P12931 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4828889 1.00 MAPK14 (0.68) MAPK14AURKAAURKBCDC7PLK4
SCHEMBL4835636 0.92 MAPK14 (0.72) MAPK14AURKAAURKBCDC7PLK4
SCHEMBL4835627 0.92 MAPK14 (0.72) MAPK14AURKAAURKBCDC7PLK4
SCHEMBL4828937 0.91 MAPK14 (0.77) MAPK14KDR
SCHEMBL4840530 0.90 MAPK14 (0.73) MAPK14SRCKDRNPC1RAB9A
SCHEMBL4840534 0.90 MAPK14 (0.73) MAPK14SRCKDRNPC1RAB9A
SCHEMBL4836051 0.90 MAPK14 (0.73) MAPK14
SCHEMBL4836044 0.90 MAPK14 (0.73) MAPK14
SCHEMBL4838900 0.90 MAPK14 (0.67) MAPK14DAPK3PRKD3PIM1CDK2
SCHEMBL4838892 0.90 MAPK14 (0.67) MAPK14DAPK3PRKD3PIM1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402589-B2 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-07-22 US claimed
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-11-03 US claimed
US-7402589-B2 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-07-22 US disclosed
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors IL1B, IL1A, IL6 MAPK14 2674/4885AURKA 4400/4885AURKB 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.